Your browser doesn't support javascript.
loading
Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study.
Chiu, Shuenn-Nan; Wang, Jieh-Neng; Fu, Yun-Ching; Chung, Hung-Tao; Chang, Ling-Yin; Wu, Mei-Hwan; Hua, Yu-Chuan; Lin, Ming-Tai; Lu, Chun-Wei; Chen, Chun-An; Wu, Jing-Ming; Wang, Jou-Kou.
Afiliação
  • Chiu SN; Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, Taipei, Taiwan.
  • Wang JN; Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.
  • Fu YC; Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Chung HT; Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Chang LY; Institute of Health Behaviors and Community Sciences, National Taiwan University, Taipei, Taiwan.
  • Wu MH; Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, Taipei, Taiwan.
  • Hua YC; Cardiac Children's Foundation Taiwan, Taipei, Taiwan.
  • Lin MT; Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, Taipei, Taiwan.
  • Lu CW; Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, Taipei, Taiwan.
  • Chen CA; Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, Taipei, Taiwan.
  • Wu JM; Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.
  • Wang JK; Department of Pediatrics, National Taiwan University Hospital and Medical College, National Taiwan University, Taipei, Taiwan. Electronic address: jkww@ntuh.gov.tw.
J Pediatr ; 195: 108-114.e1, 2018 04.
Article em En | MEDLINE | ID: mdl-29395174
OBJECTIVE: To analyze the efficacy of a novel palivizumab protocol for hemodynamically significant congenital heart disease (hsCHD) in subtropical areas without clear respiratory syncytial virus seasonality. STUDY DESIGN: Since July 2013, the National Health Insurance program has provided reimbursement for palivizumab prophylaxis with a novel monthly protocol in selected patients with hsCHD under 1 year of age. We performed a multicenter study to assess the trend of respiratory syncytial virus hospitalizations in patients with hsCHD from 2010 to 2016 during the prepalivizumab, transition, and postpalivizumab periods, and compared treatment and propensity-matched control groups. RESULTS: A total of 747 patients were enrolled in the study group and 809 in the control group. The male:female was 836:720. Cyanotic CHD was observed in 42.9% of patients. The mean age at diagnosis of CHD was 32.9 days. After 516 685 patient-days of follow-up and a mean of 3.9 doses of palivizumab in the treatment group, respiratory syncytial virus hospitalization rates decreased by 53% and 49% before and after match compared with the control group (P = .009 and .029, respectively). Hospitalization days and intensive care unit admission rate also decreased similarly in the treatment group. The efficacy of this protocol was more prominent in patients with cyanotic hsCHD. The annual respiratory syncytial virus-associated hospitalization rates also decreased significantly from the prepalivizumab to the palivizumab period (from 4.8% to 2.0%; P = .038). CONCLUSION: Palivizumab prophylaxis through the novel monthly protocol for patients with hsCHD is effective in reducing respiratory syncytial virus-related hospitalizations.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Infecções por Vírus Respiratório Sincicial / Palivizumab / Cardiopatias Congênitas / Hospitalização Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Infant / Male País/Região como assunto: Asia Idioma: En Revista: J Pediatr Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Taiwan País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Infecções por Vírus Respiratório Sincicial / Palivizumab / Cardiopatias Congênitas / Hospitalização Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Infant / Male País/Região como assunto: Asia Idioma: En Revista: J Pediatr Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Taiwan País de publicação: Estados Unidos